Evidence map›Paper›PMID 42816610›Full record

ArticleNature2026

Histone readers MLLT1 and MLLT3 concentrate AID to confer locus specificity.

Noé Seija, Sophia Gannon, Kíra A Häfner, Tim M Gemeinhardt, Jana Ridani, Diego Alvarez, Mélanie Provencher, Poorani Ganesh Subramani, Christian Poitras, Eva-Maria Piskor and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Noé SeijaInstitut de Recherches Cliniques de Montréal (IRCM), Montréal, Québec, Canada.ORCID http://orcid.org/0000-0003-2223-1291
Sophia Gannon *Institut de Recherches Cliniques de Montréal (IRCM), Montréal, Québec, Canada.
Kíra A Häfner *Institut de Recherches Cliniques de Montréal (IRCM), Montréal, Québec, Canada.ORCID http://orcid.org/0009-0008-1069-4647
Tim M Gemeinhardt *Institut de Recherches Cliniques de Montréal (IRCM), Montréal, Québec, Canada.ORCID http://orcid.org/0000-0003-0241-1009
Jana RidaniInstitut de Recherches Cliniques de Montréal (IRCM), Montréal, Québec, Canada.
Diego AlvarezSchool of Medicine, Universidad de Magallanes, Punta Arenas, Chile.ORCID http://orcid.org/0000-0003-0753-274X
Mélanie ProvencherInstitut de Recherches Cliniques de Montréal (IRCM), Montréal, Québec, Canada.
Poorani Ganesh SubramaniInstitut de Recherches Cliniques de Montréal (IRCM), Montréal, Québec, Canada.ORCID http://orcid.org/0000-0002-7318-6577
Christian PoitrasInstitut de Recherches Cliniques de Montréal (IRCM), Montréal, Québec, Canada.ORCID http://orcid.org/0000-0001-6444-7600
Eva-Maria PiskorInstitut de Recherches Cliniques de Montréal (IRCM), Montréal, Québec, Canada.ORCID http://orcid.org/0000-0003-2109-4627
Tarik MöröyInstitut de Recherches Cliniques de Montréal (IRCM), Montréal, Québec, Canada.ORCID http://orcid.org/0000-0003-4284-9849
Nicholas VonniessenDivision of Clinical and Translational Research, Department of Medicine, McGill University, Montréal, Québec, Canada.
Bruce MazerDivision of Clinical and Translational Research, Department of Medicine, McGill University, Montréal, Québec, Canada.ORCID http://orcid.org/0000-0003-4018-1419
Marcelo A NavarretteSchool of Medicine, Universidad de Magallanes, Punta Arenas, Chile.ORCID http://orcid.org/0000-0002-2044-9548
Nicole J FrancisInstitut de Recherches Cliniques de Montréal (IRCM), Montréal, Québec, Canada.ORCID http://orcid.org/0000-0002-1810-2959
François RobertInstitut de Recherches Cliniques de Montréal (IRCM), Montréal, Québec, Canada.ORCID http://orcid.org/0000-0003-1054-5920
Javier M Di NoiaInstitut de Recherches Cliniques de Montréal (IRCM), Montréal, Québec, Canada. Javier.di.noia@ircm.qc.ca.ORCID http://orcid.org/0000-0003-2896-0321

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Activation-induced deaminase (AID) drives antibody diversification through class-switch recombination and somatic hypermutation of the immunoglobulin (Ig) genes, but its off-target mutagenic activity contributes to B cell lymphoma

Identifiers

PMID42816610

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.